Nucleo-cytoplasmic transport as a therapeutic target of cancer - Wikidata - thesis-toulmin - TriplyDB

Nucleo-cytoplasmic transport as a therapeutic target of cancer

Nucleo-cytoplasmic transport as a therapeutic target of cancer

http://www.wikidata.org/entity/Q34452108

about

Mechanisms of Nuclear Export in Cancer and Resistance to Chemotherapy Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells Second- and third-generation ALK inhibitors for non-small cell lung cancer Prognostic value of immunohistochemical markers in malignant thymic epithelial tumors Integrated genetic and pharmacologic interrogation of rare cancers Cancer-causing mutations in the tumor suppressor PALB2 reveal a novel cancer mechanism using a hidden nuclear export signal in the WD40 repeat motif Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models.TMEM140 is associated with the prognosis of glioma by promoting cell viability and invasion.Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy.SUMO regulates p21Cip1 intracellular distribution and with p21Cip1 facilitates multiprotein complex formation in the nucleolus upon DNA damage CRM1 inhibitor S109 suppresses cell proliferation and induces cell cycle arrest in renal cancer cells.Chromosome region maintenance 1 expression and its association with clinical pathological features in primary carcinoma of the liver.Suppressing activity of tributyrin on hepatocarcinogenesis is associated with inhibiting the p53-CRM1 interaction and changing the cellular compartmentalization of p53 protein.ERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization.CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways.Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.Selective inhibitors of nuclear export (SINE) in hematological malignancies.Upregulation of DACT2 suppresses proliferation and enhances apoptosis of glioma cell via inactivation of YAP signaling pathway ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors.Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.Macrophages and endothelial cells orchestrate tumor-associated angiogenesis in oral cancer via hedgehog pathway activation.A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.Investigational serine/threonine kinase inhibitors against prostate cancer metastases.Mechanisms of p53 Functional De-Regulation: Role of the IκB-α/p53 Complex CRM1 Inhibitors for Antiviral Therapy.XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.Proteome-wide search for functional motifs altered in tumors: Prediction of nuclear export signals inactivated by cancer-related mutations.Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.ERK Activation Globally Downregulates miRNAs through Phosphorylating Exportin-5.Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer.XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor

P2860

Q26764837-A69FD486-B057-4450-8E09-0CEC87404F64 Q26801357-FEE6AAA9-7300-48EC-A9B3-98F75800477A Q27343176-110BA7E2-BF31-4049-8F81-621C3041F565 Q28072496-D51961D3-7D2B-4B16-BFE8-7FC2DD53256E Q28279154-F17A3F32-859B-4347-AD25-354A08284DED Q28829289-B0052714-144C-4784-B6E0-23B7FA071CD2 Q33558127-44FF0170-921D-4D24-A21A-38168633DB1A Q35764599-17F82B85-626D-49AF-898F-F2E6A23C01CA Q35843010-F86E954E-808A-4B97-8002-5089E1AF8DD3 Q35856215-C9A52D7C-4468-4D51-AD19-43D99F5BF0F9 Q35879993-0136852A-188B-477B-9D4E-5C7CD7BE533E Q36269679-0ECDE83C-F0BA-4505-9C49-01BDF9E90383 Q36393042-3FA86E38-E38F-4F9C-B225-45B7406C0EA9 Q36627593-16FEC62E-E625-471D-8FE9-5725BF7FDEA2 Q37002035-D1367616-F9CA-4D82-A61E-066CE01F8B7E Q37269298-8048D134-95FC-4026-82D4-D697CB6B3703 Q37302065-BDD10A3F-A04D-4DAA-9ACD-C600EAB29265 Q37330941-B54A25C3-00F5-429B-8AC8-2C8E5709A8A1 Q37702556-9A452982-32B3-426E-8F9D-D0B041254D33 Q38368605-98AF358D-6A3C-4252-814B-C882101057AE Q38630701-E8D35407-7F32-431C-B21C-A84755D87331 Q38640917-D23C7E4A-E331-4689-975A-B588DB4F4AD4 Q38718460-7227A9C5-B87C-4477-BEEF-03A91CB101CC Q38764010-D93D3C8F-5C15-4FFE-BD41-D7D17513AF07 Q38803563-46EE0D14-13C9-48BE-BF9F-4412D31A5F41 Q38812797-49EE7EDF-4E38-48B5-8FE9-CC25256B9246 Q38988061-BD84D752-3551-48FE-A059-70C527474FD0 Q39021945-7BAF884D-BB07-4F87-ACED-286606AEC7C2 Q39029101-6D52F5B2-2273-4FF7-8384-ECF110C6313C Q39431526-EE5CE5CC-986B-4DB8-B73C-2F5D87A37B38 Q39643726-42CE8A82-2761-4BA1-8F98-1F8B8885B360 Q39769960-DA38DD3D-7741-4618-8F5D-D669748FBE6A Q41412563-516F2167-D5DB-49AC-8B42-D520DE333B2C Q41550563-2AC83FAE-3448-4D7D-96F9-06B7357D4A00 Q44924944-536DBE99-0674-4F07-9F1A-E8BD8B34B6F4 Q49164320-89FF0A8C-0E4A-4DE6-B31A-A6D878C34C14 Q57818336-DD733813-AE66-4F82-90AF-B9F5B1D350CD Q58707427-89AE0249-0FEA-4452-AC1D-40C11FFF10E7 Q58774746-423C1AC7-F2DD-43CF-80F4-D36A50EF7DDF

P2860

Nucleo-cytoplasmic transport as a therapeutic target of cancer

http://www.wikidata.org/entity/Q34452108

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Nucleo-cytoplasmic transport as a therapeutic target of cancer

@ast

Nucleo-cytoplasmic transport as a therapeutic target of cancer

@en

Nucleo-cytoplasmic transport as a therapeutic target of cancer

@nl

type

label

Nucleo-cytoplasmic transport as a therapeutic target of cancer

@ast

Nucleo-cytoplasmic transport as a therapeutic target of cancer

@en

Nucleo-cytoplasmic transport as a therapeutic target of cancer

@nl

prefLabel

Nucleo-cytoplasmic transport as a therapeutic target of cancer

@ast

Nucleo-cytoplasmic transport as a therapeutic target of cancer

@en

Nucleo-cytoplasmic transport as a therapeutic target of cancer

@nl

P1433

Q34452108-F620DADA-FA59-4407-9D1B-BDB2B61A2ECC

P1476

Q34452108-7DADF9D1-46DB-484F-B390-BA1A8E2B0A89

P2093

Q34452108-0DBCC25D-EDAB-4CD3-90AA-F04A47A85E79

Q34452108-6061C747-8C3A-4F2E-B841-7613DB60CD03

Q34452108-7FCC4DC7-7E83-4F8B-B99C-9B25A51205B2

Q34452108-94F6C8BF-1B9A-4123-84F5-E63E88A01F2D

Q34452108-ADD570E5-6C8D-485C-B745-C0EF8289BF3C

P275

Q34452108-AA5F1E7E-A74B-4E4D-A540-88ED2DCCAA01

P2860

Q34452108-01360350-A7BA-4F0E-B985-D2CA040D06A3

Q34452108-07284298-B1FC-4F94-9DDD-3128FBC27159

Q34452108-09030A2C-78C2-43F3-ADBA-4093F47272DE

Q34452108-0D75A241-93E1-4F92-BD98-758B6C49B834

Q34452108-0EB72484-9F86-4923-BCCA-4D20A5592F3B

Q34452108-12EC3EA3-8A9A-4380-8388-A8721D0D354A

Q34452108-1339B155-792D-4F17-B7DF-F285025AFCB6

Q34452108-16E52CFE-46C3-48B9-84C1-7D4D7CC4F3CA

Q34452108-1795759C-E7E4-4DB7-978B-B8035AEA4895

Q34452108-18DA37B4-B114-45EE-9111-2F18C3069AC5

P2888

Q34452108-239BB0AE-C498-48E5-8A00-9BD7FD6C4FAE

P304

Q34452108-B44113CE-5BD9-4D04-B4C9-7D15C69F4421

P31

Q34452108-79705F1A-324E-4510-9AB0-6C15F6412881

P356

Q34452108-8AD6A96F-F061-44F3-9063-966E93AB7CA3

P478

Q34452108-E8393B90-03DC-43A4-9EEC-06F4D4813D98

P50

Q34452108-1ECCD07E-97AB-4656-B99E-53E0FFA5E973

P5008

Q34452108-14A6E091-F5E4-41B0-BCA9-465071818AFB

P577

Q34452108-AD6491E4-0724-4EED-B9E6-ACBA0CE2A13B

P5875

Q34452108-DDE68336-0454-4EC0-87CF-882E7631A9D6

P6179

Q34452108-D6ADD57D-AAB8-489A-A0A2-BF0ED0BAC459

P698

Q34452108-C29D21D8-3E13-42B5-BE36-098FE376CF22

P921

Q34452108-599A2005-0BA7-4BD1-B270-9DF6E9FFDA3D

Q34452108-7EE07DB2-144F-48EE-B90C-62AB162353D0

Q34452108-7F3D074D-1DF8-4BEE-A57F-8001439B682C

Q34452108-D214C5C0-4E92-4916-9995-D6FEB5D7393A

Q34452108-DD0601D4-8C83-4157-A988-94CD8B886EBA

P932

Q34452108-CBFC850E-18A9-4551-AD9B-42F68D3835E7

P356

S13045-014-0085-1

P1433

Journal of Hematology & Oncology

P1476

Nucleo-cytoplasmic transport as a therapeutic target of cancer

@en

P2093

Claudio Festuccia

http://www.w3.org/2001/XMLSchema#string

Dilara McCauley

http://www.w3.org/2001/XMLSchema#string

Erkan Baloglu

http://www.w3.org/2001/XMLSchema#string

Sharon Shacham

http://www.w3.org/2001/XMLSchema#string

William Senapedis

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

A code for RanGDP binding in ankyrin repeats defines a nuclear import pathway

Molecular cloning and cell cycle-dependent expression of mammalian CRM1, a protein involved in nuclear export of proteins

IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a

Epstein-Barr virus LMP1 blocks p16INK4a-RB pathway by promoting nuclear export of E2F4/5

Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region

Prognostic value of survivin in patients with gastric cancer: a systematic review with meta-analysis

Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

P2888

s13045-014-0085-1

P304

85

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13045-014-0085-1

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Giovanni Luca Gravina

P5008

P577

2014-12-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269187145

http://www.w3.org/2001/XMLSchema#string

P6179

1023868500

http://www.w3.org/2001/XMLSchema#string

P698

25476752

http://www.w3.org/2001/XMLSchema#string

P921

intracellular receptor

nuclear protein

transport protein

membrane proteins

P932

4272779

http://www.w3.org/2001/XMLSchema#string